

# Form 6b. Drug-Resistant TB Register

Name of Facility: \_\_\_\_\_

Province/ HUC: \_\_\_\_\_

Region: \_\_\_\_\_

Cohort: \_\_\_\_\_

#	Field	Definition	Format/ Legend
1	TB Case Number	Unique TB episode code generated from ITIS	<b>PSGC-NNN-A-YY-nnn</b> ; PSGC- regional and provincial code; NNN-serial number of health facility; A-patient type (R for DR-TB); YY-year; nnn-serial number of patient notified
2	Date of Screening	Date patient was screened and identified as a presumptive TB	Dates in <b>MM/DD/YYYY</b>
3	Date of Notification	Date notification form or treatment card was opened	Dates in <b>MM/DD/YYYY</b>
4	Date Start of Treatment	Date treatment was started	Dates in <b>MM/DD/YYYY</b> ; If patient is transfer-in, indicate original treatment start date and date of transfer-in in parentheses
5	Patient's Full Name	Patient's full legal name	<b>SURNAME</b> in capital letters followed by a comma then Given names followed by <b>Name extensions</b> (i.e., Jr., Sr., III) and <b>Middle name</b>
6	Date of Birth	Patient's birthdate	Dates in <b>MM/DD/YYYY</b> ; If unknown indicate June 30 and estimated year of birth
7	Age	Patient's completed years as of date of screening	<b>NN</b> in years if at least 1 year old; <b>NNm</b> (for completed months) if less than 0
8	Sex	Patient's sex	<b>M</b> - male; <b>F</b> - female
9	Permanent Address & Contact Number	Patient's permanent registered residence and current contact information	<b>House Number, Street and Village Name, and Barangay/District</b> if patient is within facility's catchment; Otherwise, put complete address including Municipality, City, Province, and Zip Code; Mobile Number <b>09xx-xxxxxxx</b> and Landline Number <b>xxxx-xxxx</b> ; add area code if patient is from outside the facility's catchment
10	Source of Patient	Main type and sub-type of facility that referred the patient for screening	<b>Pub</b> - Public (CHOs/RHUs/HCs); <b>OPub</b> - Other Public ( <b>H</b> - Hospitals, <b>J&amp;P</b> - Jails & Prisons, and <b>OG</b> - other government facilities); <b>Priv</b> - Private ( <b>H</b> - Hospitals, <b>C</b> - Clinics, and <b>OPriv</b> - other private facilities); <b>C</b> - Community ( <b>V</b> - Community Volunteer, <b>CBO</b> - Community-based Org, and <b>NGO</b> - NGO/CSO)
11	Mode of Screening	Approach done in finding the patient	<b>PCF</b> - Passive Case Finding; <b>ACF</b> - Active Case Finding; <b>ICF</b> - Intensified Case Finding; <b>ECF</b> - Enhanced Case Finding
12	Anatomical Site	Classification of TB case according to organ affected by the disease	<b>P</b> - Pulmonary; <b>EP</b> - Extra-pulmonary; if EP, specify site; if both P and EP, indicate P
13	Registration Group	Classification of TB case based on history of TB treatment	<b>N</b> - New; <b>R</b> - Relapse, <b>TAF</b> - Treatment After Failure; <b>TALF</b> - Treatment After LTFU; <b>PTOU</b> - Prev. Tx Outcome Unk; <b>UH</b> - Unknown History
14	TB Bacteriological Status	Classification of TB case according to laboratory diagnostic test results	<b>BC</b> - Bacteriologically-confirmed; <b>CD</b> - Clinically-diagnosed
15	DR-TB Bacteriological Status	Classification of TB case according to drug susceptibility testing and clinical decision	<b>BC RR</b> - Bacteriologically-confirmed Rif-resistant; <b>BC MDR</b> - Bacteriologically-confirmed Multidrug-resistant; <b>BC XDR</b> - Bacteriologically-confirmed Extensively drug-resistant; <b>CD MDR</b> - Clinically-diagnosed Multidrug-resistant; <b>OD</b> - Other drug-resistant (includes polydrug-resistant and monodrug-resistant)
16	Treatment Regimen at Start	Regimen type upon enrollment	<b>3</b> - SSOR 4LfxBdq(6)CfzPtoEZHdH/5LfxCfzZE; <b>4</b> - SLOR FQ-S 6LfxBdqLzdCfz/12LfxLzdCfz; <b>5</b> - SLOR FQ-R 6LzdBdqDlmCfzCs; <b>6a/b/c</b> - Pedia MDR FQ-S [a - LfxLzdCfzCs(Pas/Eto), b - LfxLzdCfzCs(Dlm/PAS), c - BdqLfxLzdCfz (Cs/Dlm)]; <b>7a/b/c</b> - Pedia MDR FQ-R [a - LzdCfzCsPAS(Eto/Dlm), b - LzdCfzCsDlm(PAS/Eto), c - BdqLzdCfzCs(Dlm/PAS)];
17	Treatment Regimen at 6th Month	Regimen type at end of 6th month of treatment	<b>BPAL</b> ;
18	Treatment Regimen at End	Regimen type upon last day of treatment	<b>ITR</b> - individualized treatment regimen (specify drugs & duration)
19	Number of Contacts	Number of contacts (Contact - a person who shared an enclosed space, such as the household, a social gathering place, workplace or facility, for extended periods within the day with the index case during the 3 months before diagnosis of TB)	<b>NN</b> (Identified - number declared by the patient as his/her household or close contact; <b>Tested</b> - among identified, number who submitted sputum for testing; <b>Diagnosed</b> - among tested, number of bacteriologically confirmed or clinically diagnosed to have active TB; <b>Treated</b> - among diagnosed, number who started on treatment)
20	HIV Status & Test Date	Result of HIV Testing and date HIV test was administered Date of counselling may be written temporarily in pencil	<b>NR</b> - non-reactive; <b>R</b> - reactive (in pencil while awaiting confirmatory test results); <b>N</b> - negative, <b>P</b> - positive; Dates in <b>MM/DD/YYYY</b>
21	DM Status & Test Date	Result of Diabetes Mellitus Screening/Risk Assessment and date DM test was administered; Date of counselling may be written temporarily in pencil	<b>(+)</b> - with DM; <b>(-)</b> - without DM; Dates in <b>MM/DD/YYYY</b>
22	Location of Treatment	Type of treatment location	<b>FB</b> - facility based (RHU/HC/BHS); <b>CB</b> - community-based (workplace, common meeting place); <b>HB</b> - home-based; add <b>DAT</b> - digital adherence tool used and specify ( <b>99DOTS, VDOT, MedBox</b> )
23	Type of Treatment Supporter	Type of treatment supporter	<b>HCW</b> - Health Care Worker, <b>F</b> - Family, <b>V</b> - Volunteer (non-related), <b>O</b> - Others
24	Date Transferred	Date patient was endorsed to treatment supporter	Dates in <b>MM/DD/YYYY</b>
25	Drug Susceptibility Testing	Result of in-vitro testing using either phenotypic methods to determine susceptibility or molecular techniques to detect resistance-conferring mutations to a medicine	<b>S</b> - susceptible; <b>R</b> (in red) - resistant; Add <b>"(LPA)"</b> if method is LPA; <b>I</b> - Indeterminate/Invalid/Error; <b>C</b> - Contaminated; <b>ND</b> - Not Done; <b>N/A</b> - Not Applicable
26	Xper MTB/RIF	Result of a cartridge-based nucleic acid amplification test (NAAT)	<b>T</b> - MTB detected, Rifampicin resistance not detected; <b>RR</b> - MTB detected, Rifampicin resistance detected; <b>TI</b> - MTB detected, Rifampicin resistance indeterminate; <b>N</b> - MTB not detected; <b>I</b> - Invalid/ No result/ Error; <b>ND</b> - Not Done; Dates in <b>MM/DD/YYYY</b>
	TB Smear Microscopy	Result of testing specially stained smears using brightfield or fluorescence microscopy Space can also be used for TB LAMP results	Smear: <b>0</b> - no AFB seen / no AFB observed in 1 length; <b>+n</b> (in red) - n AFB seen in 1 length / 5-49 AFB in 1 length / 3-24 AFB in 1 length; <b>1+</b> (in red) - 10-99 AFB seen in 1 length / 3-24 AFB in 1 field / 1-6 AFB in in 1 field; <b>2+</b> (in red) - 1-10 AFB/ OIF, at least 50 fields / 25-250 in 1 field / 7-60 in 1 field; <b>3+</b> (in red) - >10 AFB/ OIF, at least 20 OIF / > 250 in 1 field / >60 in 1 field; <b>ND</b> - Not Done; <b>N/A</b> - Not Applicable TB LAMP: <b>P</b> (in red) - MTB detected, the sample fluoresce under the UV light; <b>N</b> - MTB not detected, the sample did not fluoresce under the UV light; <b>I</b> - Sample with incomplete fluorescence as compared to the positive control; this should be repeated using the same sample. If the second test result is still the same, release the result as Indeterminate Dates in <b>MM/DD/YYYY</b>
	TB Culture	Result of a laboratory test involving growing the bacteria on solid or liquid medium	<b>MTb</b> (in red) - Mycobacterium tuberculosis positive; <b>0</b> - No growth; <b>NTM</b> - Non-tuberculous Mycobacteria; <b>C</b> - Contaminated; <b>ND</b> - Not Done; <b>N/A</b> - Not Applicable
27	Treatment Outcome	Evaluation of completion of treatment based on laboratory follow-up results, number of doses taken, and clinical improvement	<b>Cured; Treatment Completed; Died; Failed; LTFU</b> - Lost to Follow-up Dates in <b>MM/DD/YYYY</b> ; Indicate short reason if Died, Failed, or LTFU
28	Post Treatment Follow-up	Results of laboratory tests done during follow-up after treatment completion	See legend on Smear and Culture in Column 25
29	Post Treatment Outcome	Evaluation at one year after treatment outcome based on laboratory test results, chest x-ray, and clinical assessment	<b>NR Cure</b> - Non-relapsing Cure; <b>Relapse; Died; LTFU</b> - Lost to Follow-up
30	Remarks	Other notes on the patient	PhilHealth Number, Research participation, etc.

(1) TB Case Number	(2) Date of Screening (MM/DD/YYYY)	(5) Patient's Full Name (SURNAME, Given Names Name Extension and Middle Name)	(6) Date of Birth (MM/DD/YYYY)	(9) Permanent Address & Contact Number (House No., Street, Barangay, City/Municipality, Province, Region & include Area Code for telephone no.)	(10) Source of Patient (see legend)	(13) Registration Group (see legend)	(16) Treatment Regimen at Start (see legend)	(19) Number of Contacts Identified/ Tested/ Diagnosed/ Started on Tx (Adults and Children)				(20) HIV Status (see legend) & Test Date (MM/DD/YYYY)	(22) Location of Tx (FB/CB/HB & DAT-specify)
	(3) Date of Notification (MM/DD/YYYY)		(7) Age		(11) Mode of Screening (P / A/ I/ E)	(14) TB Bacteriological Status (BC/CD)	(17) Treatment Regimen at 6th Month (see legend)					(23) Type of Tx Supporter (HCW/ F/ V/ O)	
	(4) Date Start of Treatment (MM/DD/YYYY)		(8) Sex (M/F)		(12) Anatomical Site (P/EP-specify)	(15) DR-TB Bacteriological Status (see legend)	(18) Treatment Regimen at End (see legend)	Identified	Tested	Diagnosed	Treated	(21) DM Status (see legend) & Screening Date (MM/DD/YYYY)	(24) Date Transferred (MM/DD/YYYY)
1													
2													
3													
4													
5													

